Renibus Therapeutics, Inc. announced it raised $16.3 Million in an amended filing from an offering of $35 Million

Company

Location

About

Renibus is a clinical-stage biopharmaceutical company focused on preventing disease progression, protecting against organ damage, and improving outcomes in cardiorenal diseases. Its pipeline includes first-in-class therapies that activate cytoprotective pathways. Lead candidate RBT-1, currently in Phase 2 for cardiac surgery, will enter Phase 3 trials to reduce complications post-cardiothoracic surgery. Other programs include RBT-2 for slowing CKD progression, RBT-3 for preventing cisplatin-induced nephrotoxicity, and RBT-9, an anti-inflammatory compound that showed promise in reducing hospital stays in COVID-19 patients.